ArticleInternational journal of hypertension2013
The Angiotensin-melatonin axis.
Article in International journal of hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 91 citations in OpenAlex.
- Melatonin Therapy Improves Cardiac Autonomic Modulation in Pinealectomized Patients.Frontiers in endocrinology · 2020Trial
- Circadian Blood Pressure as an Indicator for Cardiovascular Complications : CBP as an Indicator for Cardiovascular Complications.Galen medical journal · 2025Review
- Efficacy of a Neuroimmune Therapy Including Pineal Methoxyindoles, Angiotensin 1-7, and Endocannabinoids in Cancer, Autoimmune, and Neurodegenerative Diseases.Clinical interventions in aging · 2025Article
- Melatonin: a ferroptosis inhibitor with potential therapeutic efficacy for the post-COVID-19 trajectory of accelerated brain aging and neurodegeneration.Molecular neurodegeneration · 2024Review
- Rs4862705 in the melatonin receptor 1A gene is associated with renal function decline in type 1 diabetes individuals.Frontiers in endocrinology · 2024Article
- Impaired Melatonin Secretion, Oxidative Stress and Metabolic Syndrome in Night Shift Work.Antioxidants (Basel, Switzerland) · 2023Review
- Multiplatform-Integrated Identification of Melatonin Targets for a Triad of Psychosocial-Sleep/Circadian-Cardiometabolic Disorders.International journal of molecular sciences · 2023Article
- Melatonin as a Potential Approach to Anxiety Treatment.International journal of molecular sciences · 2022Review
- Melatonin Improves Ischemia-Induced Circulation Recovery Impairment in Mice with Streptozotocin-Induced Diabetes by Improving the Endothelial Progenitor Cells Functioning.International journal of molecular sciences · 2022Article
- Developmental and Early Life Origins of Hypertension: Preventive Aspects of Melatonin.Antioxidants (Basel, Switzerland) · 2022Review
- Role of melatonin in respiratory diseases (Review).Experimental and therapeutic medicine · 2022Review
- Urinary Angiotensinogen-Melatonin Ratio in Gestational Diabetes and Preeclampsia.Frontiers in molecular biosciences · 2022Article
- Melatonin as a Potential Adjuvant Treatment for COVID-19 beyond Sleep Disorders.International journal of molecular sciences · 2021Review
- Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2021Review
- Melatonin exerts a neuroprotective effect against γ-radiation-induced brain injury in the rat through the modulation of neurotransmitters, inflammatory cytokines, oxidative stress, and apoptosis.Environmental science and pollution research international · 2021Article
- Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients?Diseases (Basel, Switzerland) · 2020Review
- Melatonin as a protective agent in cardiac ischemia-reperfusion injury: Vision/Illusion?European journal of pharmacology · 2020Review
- Melatonin potentials against viral infections including COVID-19: Current evidence and new findings.Virus research · 2020Review
- The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions.Life sciences · 2020Review
- Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.Life sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence indicates that various biological and neuroendocrine circadian rhythms may be disrupted in cardiovascular and metabolic disorders. These circadian alterations may contribute to the progression of disease. Our studies direct to an important role of angiotensin II and melatonin in the modulation of circadian rhythms. The brain renin-angiotensin system (RAS) may modulate melatonin synthesis, a hormone with well-established roles in regulating circadian rhythms. Angiotensin production in the central nervous system may not only influence hypertension but also appears to affect the circadian rhythm of blood pressure. Drugs acting on RAS have been proven effective in the treatment of cardiovascular and metabolic disorders including hypertension and diabetes mellitus (DM). On the other hand, since melatonin is capable of ameliorating metabolic abnormalities in DM and insulin resistance, the beneficial effects of RAS blockade could be improved through combined RAS blocker and melatonin therapy. Contemporary research is evidencing the existence of specific clock genes forming central and peripheral clocks governing circadian rhythms. Further research on the interaction between these two neurohormones and the clock genes governing circadian clocks may progress our understanding on the pathophysiology of disease with possible impact on chronotherapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.